[Heavy ion therapy for non-small cell lung cancer--new, radical radiotherapy for advanced-age patients as an alternative to surgery].
Clinical trials of carbon beam radiotherapy for stage I non-small cell lung cancer (NSCLL), and their results, are briefly described. The local control rate, cause-specific and overall survival rates of 146 patients with clinical stage I NSCLC were 82.0%, 59.0% and 59.0%, respectively. Radiation pneumonia was not serious and infrequent (2.1%). In the phase II clinical study, the local control rate of 50 patients was 100% without radiation pneumonia, resulting in a 74.0% overall survival rate. Carbon beam therapy could be an alternative to surgery, especially for lung cancer patients of advanced age and/or with complications. For locally advanced lung cancer treated with carbon beams, excellent local control as in stage I NSCLC has been demonstrated, providing hopeful prospects for the treatment of lung cancer.
Miyamoto
Tadaaki
T
Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000532:radiotherapy*; D063193:Heavy Ion Radiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011880:Radiotherapy Planning, Computer-Assisted; D011882:Radiotherapy, High-Energy; D015996:Survival Rate